Linscomb Wealth Inc. Boosts Position in Becton, Dickinson and Company $BDX

Linscomb Wealth Inc. raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 11,745 shares of the medical instruments supplier’s stock after purchasing an additional 890 shares during the period. Linscomb Wealth Inc.’s holdings in Becton, Dickinson and Company were worth $2,023,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BDX. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. Private Trust Co. NA grew its holdings in Becton, Dickinson and Company by 3.9% during the first quarter. Private Trust Co. NA now owns 3,866 shares of the medical instruments supplier’s stock valued at $886,000 after purchasing an additional 145 shares during the period. D.A. Davidson & CO. grew its holdings in Becton, Dickinson and Company by 37.6% during the first quarter. D.A. Davidson & CO. now owns 49,966 shares of the medical instruments supplier’s stock valued at $11,445,000 after purchasing an additional 13,648 shares during the period. Calamos Advisors LLC grew its holdings in Becton, Dickinson and Company by 1.1% during the first quarter. Calamos Advisors LLC now owns 61,868 shares of the medical instruments supplier’s stock valued at $14,171,000 after purchasing an additional 688 shares during the period. Finally, 44 Wealth Management LLC bought a new stake in Becton, Dickinson and Company during the first quarter valued at about $414,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $178.77 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $51.24 billion, a P/E ratio of 32.15, a P/E/G ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The business’s 50-day moving average is $188.38 and its 200 day moving average is $183.17.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BDX shares. Wells Fargo & Company upped their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Morgan Stanley upped their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Argus upped their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $205.40.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 1,895 shares of company stock valued at $358,995 in the last quarter. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.